{"id":"W4386270917","doi":"10.1016/s2152-2650(23)00762-0","title":"POSTER: IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"Universitat de Barcelona; Rigshospitalet; Universitair Medisch Centrum Groningen; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; Gentofte Hospital; Rijksuniversiteit Groningen; Odense Universitetshospital; Helsingin Yliopisto","keywords":"Refractory (planetary science); Follicular lymphoma; Medicine; Safety profile; Follicular phase; Oncology; Internal medicine; Lymphoma; Intensive care medicine; Adverse effect; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007891047,0.0005643177,0.0008522345,0.0001963715,0.0002435866,0.0008957603,0.0004301887,0.0005755525,0.008090071],"category_scores_gemma":[0.0006528572,0.0001792996,0.0007342384,0.0002079075,0.0002266627,0.0004388282,0.0001996655,0.001741922,0.002182289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004623706,"about_ca_system_score_gemma":0.0004720314,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000462137,"about_ca_topic_score_gemma":0.001636395,"domain_scores_codex":[0.9998191,0.00005176851,0.00001558675,0.00002891807,0.00003546148,0.00004907218],"domain_scores_gemma":[0.9997196,0.00006373101,0.00007805099,0.00001829633,0.00003596965,0.00008438094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1111581,0.004638278,0.00985446,0.00220478,0.002456223,0.0004850262,0.0001770348,0.00120143,0.06346712,0.0004892309,0.07644159,0.7274267],"study_design_scores_gemma":[0.2592235,0.1716766,0.1963639,0.001195717,0.00766474,0.004942134,0.0002539179,0.003425754,0.04818134,0.001429437,0.3054258,0.0002171075],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.862879,0.07854901,0.002268052,0.0092624,0.002744892,0.001296721,0.006876634,0.0007457566,0.03537763],"genre_scores_gemma":[0.9540209,0.01681437,0.001956281,0.006677497,0.001413512,0.0003948747,0.005441505,0.0001041981,0.01317685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008090071,"threshold_uncertainty_score":0.02706403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01785555600089784,"score_gpt":0.2902768768952964,"score_spread":0.2724213208943986,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}